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Objective: Endothelial dysfunction (ED) plays a role in diabetic cardiovascular
complications. Hyperglycemia increases cytockines involved in vascular
inflammation. Inhibition of phosphodiesterase type 5 (PDE5) exerts a relaxa-
tion on corpora cavernosa and has cardioprotective properties. The effect of
chronic sildenafil treatment, on ED markers and metabolic parameters in a
non-randomized study onmenwith type 2 diabetes (T2DM), was investigated.
Research design and methods: Twenty-eight T2DM patients (61.2 ± 7.8 years,
hemoglobin A1c (HbA1c) 7.9 ± 1.3%, duration of diabetes 11.5 ± 7.8 years)
were treated with sildenafil 100 mg/d for 3 months. Baseline and postprandial
glycemia, insulin, HbA1c, HOMA index, lipids, glomerular filtration rate,
homocysteine were assessed at each visit. P-selectin (CD62P), CD14/42b,
CD14/41, ICAM (CD54), PECAM (CD31) and CD11b/CD18, were evaluated, after
monocyte isolation with flow-cytometry, before and after treatment.
Results: After 3 months, sildenafil decreased P-selectin (p < 0.05), post-
prandial glycemia (p < 0.01), HbA1c (p < 0.01), low-density lipoprotein
cholesterol (p < 0.01) and increased high-density lipoprotein (p < 0.05).
Conclusions: PDE5 inhibition, in T2DM patients, reduces the endothelial
function marker P-selectin and exerts a beneficial effect on glycometabolic
control.
Keywords: phosphodiesterase type-5 inhibitors, P-selectin, sildenafil, type 2 diabetes
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1. Introduction
Endothelial dysfunction (ED), defined as an abnormal response leading to a reduc-
tion in the bioavailability of nitric oxide (NO) and impaired vasodilation, is involved
in the pathogenesis of vascular complications of type 2 diabetes mellitus (T2DM). It
is accepted that standard cardiovascular disease (CVD) risk factors do not adequately
explain the excess CVD in diabetes and heightened inflammation. An early finding
of ED, induced by chronic hyperglycemia, is the release of chemokines such as
Monocyte Chemoattractant Protein-1 and others molecules, from endothelium [1],
involved in inflammatory pathways of vascular damage. These factors increase the
expression of interstitial and vascular cellular adhesion molecules (such as selectins)
that attract monocytes and immunocytes to the stressed site [2]. Moreover, according
to experimental evidence, hyperglycemia increases reactive oxygen species (ROS)
production that decreases the bioavailability of NO, leading to an impaired
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endothelial relaxation. Patients with diabetes are characterized
by a reduced response to vasoactive agents [3,4].
Sildenafil is the first specific phosphodiesterase type-5 inhib-
itor (PDE5i) marketed for the treatment of erectile dysfunc-
tion. Inhibition of PDE5 exerts a relaxant effect on the
smooth muscle cells of the trabecular structures in the corpora
cavernosa by increasing NO availability [3,4]. PDE5 isozyme is
widely expressed in the vasculature and recently, promising
cardioprotective effects of long-term daily PDE5i administra-
tion have been demonstrated in a randomized placebo-
controlled trial and in a meta-analysis matching > 1600
patients [5-7].
However, the efficacy of PDE5 inhibitor, used for the treat-
ment of erectile dysfunction, seems to be lower in patients
with diabetes compared with those without diabetes [3]. It
has been suggested that a diffuse ED is responsible for this
lack of response and recently it has been demonstrated in a
systematic review of literature that chronic PDE5i administra-
tion exerts a beneficial effect on endothelial function, improv-
ing flow-mediated dilation and serum pro-inflammatory
markers (IL6) in diabetic men [8]. The aim of the present
study was to determine the effect of chronic therapy with a
selective PDE5i, sildenafil, on ED markers and metabolic
control in T2DM patients.
2. Patients and methods
Eligible men were recruited from the outpatient clinics of Poli-
clinico Umberto I, ‘Sapienza’ University Hospital of Rome
between 2008 and 2009. The inclusion criteria were as follows:
T2DM, age 35 -- 75 years; diabetes duration > 1 year; hemo-
globin A1c (HbA1c) < 10% (53 mmol/mol); normal blood
pressure or treated hypertension with achievement of a target
of < 130/80 mm Hg; and body mass index < 40 kg/m2. The
exclusion criteria were as follows: use of exogenous insulin,
thiazolidinediones, or spironolactone; prior or current use of
PDE5 inhibitors; substance abuse; history of CVD, prolifer-
ative retinopathy, or autonomic neuropathy; symptoms or
signs of ischemic heart disease during cardiac evaluations
at enrollment and contraindications to sildenafil use. Concom-
itant medications (e.g., antihypertensives, statins, oral antidia-
betic medications) could not be changed between the 3months
before the study. All subjects gave their written informed
consent. The protocol was approved by the hospital ethics
committee.
2.1 Study design
This study was conducted in T2DM patients consecutively
enrolled to receive 100 mg/day sildenafil in fractioned dose
(25 mg at 8 AM plus 25 mg at 4 PM plus 50 mg at
10 PM). Patients were monitored monthly for the entire
study duration. The study was designed, conducted, and
monitored by the study team without industry support.
2.2 Laboratory investigations
The following parameters were assessed at each visit: baseline
and postprandial glycemia, insulin, HbA1c, homeostasis
model assessment index (HOMA index), lipid profile, glomer-
ular filtration rate (GFR), omocistein and vital signs. Endothe-
lial function markers, P-selectin (CD62P) and inflammatory
indices, CD14/42b, CD14/41, ICAM (CD54), PECAM
(CD31) and CD11b/CD18 were measured before starting
sildenafil and after 3 months of treatment.
2.2.1 Antibodies and other reagents
Monoclonal antibodies directly conjugated to fluorochromes
used in this study were purchased from the following sources:
PE-conjugated CD14 (IgG2a) and CD11b (IgG2a) and
FITC-conjugated CD41 (IgG1), CD54 (IgG2b), CD31
(IgG1) and CD18 (IgG1) were obtained from SigmaChemical
Company (Sigma, Aldrich; Milano, Italy); FITC-conjugated
CD42b (IgG1) and CD62P (IgG1) were obtained from
BioLegend (San Diego, California).
2.2.2 Monocytes isolation and immunolabeling
Blood samples were collected in heparizined tubes (10 IU/
ml). Monocytes were isolated after centrifugation of the blood
with a polysucrose-sodium diatrizoate solution, 1.077 g/ml
density and 280 mOsm osmolarity (Lymphoprep; Nycomed,
Oslo, Norway) at 800g at 20C. The mononuclear cell layer
was collected and the cells were thus washed two times in a
solution of cold phosphate-buffered saline (PBS, pH 7.2),
supplemented with 1% fetal calf serum and 2 mmol/l
EDTA (Sigma, Aldrich, Milano, Italy). The cell suspension
was then incubated with an anti-CD14 antibody (attached
on microbead surface) (Miltenyi Biotec, Bergisch Gladbach,
Germany) to separate the monocytes from other mononuclear
cells [9]. The monocytes obtained (50 µl/1  106/ml) were
washed and resuspended at a concentration of 1  106/ml
in PBS and then incubated with a designed amount of specific
paired FITC- and PE-conjugated antibodies for 30 min at
room temperature. The different combinations were immu-
nostained with different combinations of the following anti-
bodies: PE-conjugated CD14 and FITC-conjugated
CD42b, PE-conjugated CD14 and FITC-conjugated P-selec-
tin (CD62P), PE-conjugated CD14 and FITC-conjugated
CD41, PE-conjugated CD14 and FITC-conjugated ICAM
(CD54), PE-conjugated CD14 and FITC-conjugated
PECAM (CD31) and PE-conjugated CD11b and FITC-
conjugated CD18. Then, 2 ml of PBS were added to all tubes.
Cells were resuspended in 0.5 ml of 2% paraformaldehyde
after 10 min centrifugation at 500 g and careful supernatant
removal.
2.2.3 Flow cytometry
Two-color flow cytometry was used to identify the proportion
of monocytes forming aggregates with platelets. Samples
were run through a Beckman-Coulter XL2 flow cytometer,
E. Mandosi et al.




















































and data analysis was performed using EXPO32 (Beckman-
Coulter) software. For molecular mechanism studies of
platelet--monocyte binding, samples were preincubated with
saturating concentrations of inhibitory mAb for 15 min
before labeling. Platelet--monocyte adhesion was determined
using directly conjugated CD14-PE and CD42b-FITC
mAb. Leukocyte/platelet fluorescence levels using these anti-
bodies were unaltered by heparin and EDTA treatment.
2.3 Statistical analysis
Continuous variables are reported as mean ± 1 SD. Analysis
were performed, as appropriate, by Student’s t-test, two-way
repeated-measures ANOVA, and post hoc comparison
(Newman--Keuls and Bonferroni test). Statistical analyses
were performed with the use of SPSS for Windows, version
18.0 (SPSS, Inc., Chicago, IL, USA). All statistical compari-
sons were performed with two-tailed significance tests, with
p < 0.05 considered statistically significant.
3. Results
All the twenty-eight patients completed the study. They were
assigned to receive sildenafil (n = 28, mean age = 61.2 ±
7.8 yrs, duration of diabetes = 11.5 ± 7.8 yrs) and monitored
for 3 months. There were no drug-related adverse events.
After 3 months, P-selectin was reduced in the treated group
(3.35 ± 3.51 vs 1.79 ± 1.1 %; p < 0.05) (Figure 1) and
(Table 1). Moreover, in these patients a significant reduction
in post prandial glycemia (10.1 ± 3.1 vs 8.8 ± 2.9 mmol/l;
p < 0.01), HbA1c (7.9 ± 1.3 vs 7.3 ± 1.1 %; p < 0.01),
low-density lipoprotein cholesterol (3.01 ± 0.98 vs 2.7 ±
0.9 mmol/l; p < 0.01), and a significant increase in high-
density lipoprotein cholesterol (1.05 ± 0.2 vs 1.13 ±
0.2 mmol/l; p < 0.05) were observed (Table 2).
The CD14/42b, CD14/41, ICAM, PECAM and CD11b/
CD18 levels were unchanged after sildenafil treatment
(Table 1). At baseline, a significant correlation was observed
only between P-selectin and CD14/41 (p = 0.01, data not
shown), but after treatment this correlation was not found.
4. Discussion
This study shows that a 3-month treatment with sildenafil at a
dose of 100 mg/day improves endothelial function marker
(P-selectin) and metabolic control in men with T2DM.
Poor glycemic control and associated hyperglycemia are
related to the development of vascular complications in diabe-
tes through promotion of ED and atherosclerosis, a chronic
and progressive disease characterized by an inflammatory
response of the arterial wall [10]. The development of athero-
sclerotic plaques is influenced by oxidative stress, an
imbalance between the accumulation of ROS and limited
antioxidant defences; this imbalance compromises NO avail-
ability and leads to ED [11,12]. The presence of ED represents
a major promoter for atherosclerosis and thrombosis and it is
an independent prognostic predictor for the risk of future car-











Figure 1. P-selectin reduction in Sildenafil-treated patients.
*p < 0.05.
Table 1. Endothelial function and inflammation
markers in sildenafil-treated patients.
Sildenafil (n = 28)
% Baseline 3 months follow-up
P-selectin 3.35 ± 3.51 1.79 ± 1.1*
CD14/42b 6.78 ± 8.82 6.63 ± 12.37
CD14/41 12.39 ± 13.67 13.45 ± 18.36
ICAM 67.72 ± 27.6 62.0 ± 30.5
PECAM 98.66 ± 3.7 99.39 ± 0.69
CD11b/CD18 99.49 ± 0.49 99.14 ± 1.18
*p < 0.05.
Table 2. Metabolic parameters in Sildenafil-treated
patients.
Sildenafil (n = 28)
Metabolic parameters Baseline 3 months
Basal Glycemia (mmol/l) 8.4 ± 2.4 8.0 ± 2.4
Post-prandial Glycemia (mmol/l) 10.1 ± 3.1 8.8 ± 2.9 *
HOMAi 8.1 ± 6.1 7.9 ± 7.9
HbA1c (%) 7.9 ± 1.3 7.3 ± 1.1*
Total Cholesterol (mmol/l) 4.78 ± 1.0 4.5 ± 0.87
HDL Cholesterol (mmol/l) 1.05 ± 0.2 1.13 ± 0.2*
LDL Cholesterol (mmol/l) 3.01 ± 0.98 2.7 ± 0.9*
Triglycerides (mmol/l) 1.51 ± 0.7 1.54 ± 0.7
eGFR (ml/min) 87.8 ± 16.5 86.0 ± 16.4
CrCl (ml/min) 141.7 ± 42.4 132.4 ± 34.4
Omocistein (µmol/L) 11.5 ± 3.8 12.9 ± 3.5
*p < 0.05.
CrCl: Creatinine clearance; eGFR: Estimated glomerular filtration rate; HbA1c:
Hemoglobin A1c; HDL: High-density lipoprotein; HOMAi: Homeostasis model
assessment index; LDL: Low-density lipoprotein.
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need for drugs to improve endothelial function and to reduce
the progression of atherosclerosis [13,14].
Hyperglycemia may be linked to ED and atherogenesis
through the production of inflammatory factors that play an
important role in recruiting monocytes, neutrophils, and lym-
phocytes in the site of endothelium damage [15]. This study
demonstrated that sildenafil decreases P-selectin in men with
T2DM. Other authors did not observe an effect of sildenafil
treatment on oxidative stress biomarkers or cytokines, proba-
bly because of the short duration of the treatment [16].
P-selectin is involved in the pathogenesis of ED and athero-
sclerosis calling monocytic cells in the site of vascular injury.
The selectins mediate adhesion of hematopoietic cells to vas-
cular surfaces and to each other [17]. P-selectin acts binding
to a specific receptor, the pSGL-1, expressed by all leukocytes:
neutrophils, NK cells, monocytes, T-lymphocytes. It is
involved in the interaction between leukocytes themselves
and the endothelium and between platelets and endothelium.
Treatment with sildenafil, reducing the levels of P-selectin,
could therefore play a role in improving the ED associated
with diabetes mellitus [3-6]. This mechanism might underline
the effects of PDE5i in improving parameters of endothelial
function as recently shown in a recent meta-analysis in
T2DM patients [8]. During the last years, sildenafil has
evolved from possible anti-angina drug to the treatment of
erectile dysfunction and more recently it has found a new
place in the treatment of pulmonary hypertension.
In addition, potential cardioprotective effects of long-term
daily PDE5i administration have been demonstrated in a
large (>1600 patients) meta-analysis of placebo-controlled tri-
als on heart architecture and performance [7].
The results of the present study could indicate that the
effect of sildenafil is exerted not only at a hemodynamic level,
inducing vasodilation, but also on a marker involved in vascu-
lar damage in diabetes. Chronic administration of this drug in
patients with diabetes mellitus might act on some of the
mechanisms involved in the pathogenesis and progression of
diabetic vascular complications.
Moreover, this study suggests that chronic PDE5
inhibition improves glycometabolic control in patients with
type 2 diabetes. It has been demonstrated that chronic
treatment with sildenafil improves energy balance and
enhances insulin action in vivo, in a mouse model [18].
Phosphodiesterase-5 is the predominant phosphodiesterase
in vascular smooth muscle and the inhibition of
PDE5 results in smooth muscle relaxation and vasodilation.
In addition to modulating vascular tone, cGMP signaling
can also regulate muscle glucose uptake [18]. A potential mech-
anism by which phosphodiesterase-5 inhibition may improve
insulin action could be through the prevention of ED, charac-
terized by decreased levels of NO, reduced production of
cGMP and altered muscle glucose uptake. There is evidence
supporting that ED may be causative of insulin resistance
and T2DM [19,20].
Moreover, recent data demonstrated that the inhibition of
PDE5 plays a role in the regulation of energy homeostasis in
mouse skeletal muscle cells, increasing fatty acid oxidation [21].
Furthermore, sildenafil has been shown to cross the blood-
brain barrier, and phosphodiesterase-5 expression has been
detected in the brain. Thus, the enhanced insulin action
may also result from an effect on the central nervous sys-
tem [22]. This study has some limitations, such as the lack of
placebo-controlled group and the treatment duration,
3 months, which is not sufficient to evaluate the effects of a
longer sildenafil therapy in a real-life clinical set.
5. Conclusion
The results of this study indicate that the chronic inhibition of
PDE5 reduces a biomarker of vascular damage and improves
the glycometabolic control in patients with T2DM.
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